Synapse - Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) Meeting Abstract

Authors:	Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; Noy, A.; Batlevi, C. L.; Hamilton, A.; Owens, C.; Matasar, M. J.; Palomba, M. L.; Lee, C. Y.; Falchi, L.; Johnson, W. T.; Schoder, H.; Dogan, A.; Bunyaviroch, T.; Seshan, V.; Salles, G.; Younes, A.; Von Keudell, G.
Abstract Title:	Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
Meeting Title:	63rd Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	138
Issue:	Suppl. 1
Meeting Dates:	2021 Dec 11-14
Meeting Location:	Atlanta, GA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2021-11-23
Language:	English
ACCESSION:	WOS:000736413901177
DOI:	10.1182/blood-2021-154226
PROVIDER:	wos
Notes:	Meeting Abstract: 2447 -- Hybrid meeting, also took place online -- Source: Wos